- Despite incredible advances in medicine, cancer is still affecting millions.
- New cases are expected to be 33% higher in 2023 compared to 2009.
- Today’s 100-rated Power Stock is a biopharma company that develops medicines for difficult-to-treat cancers and other diseases.
|  | Eric Montross is a big man.
He stands 7 feet tall and is best known for leading the North Carolina Tar Heels to the 1993 NCAA basketball national championship.
After college, he was a first-round pick of the Boston Celtics and spent eight years in the NBA.
He was quite the imposing figure on the basketball court.
Now, he is a radio analyst for his alma mater and helps raise money for the university’s athletic department.
Last week Montross’ family announced that he is battling cancer.
The announcement put cancer back in the headlines, albeit for a short time.
While COVID-19 and other new viruses and illnesses were the biggest topics in the medical world over the last couple of years, researchers remain focused on innovations to treat cancer.
And that’s for good reason…
The American Cancer Society expects 1.6 million new cases of cancer in the U.S. this year:  (Click here to view larger image.) Despite advances in the treatment of cancer, that’s a 33.8% increase from 2009.
This tells me that cancer is still affecting our society in a huge way.
Several pharmaceutical companies are racing for a cure, so I dug through our Stock Power Ratings system and found one making tremendous headway.
Click here (or keep reading) to reveal this ticker. 
Zymeworks Inc. (Nasdaq: ZYME) scores a “Strong Bullish” 100 out of 100 in our proprietary Stock Power Ratings system.
That means we expect it to beat the broader market by 3X in the next 12 months.  (Click here to view larger image.) The company, in partnership with Jazz Pharmaceuticals PLC (Nasdaq: JAZZ), has developed zanidatamab — a medicine that when coupled with chemotherapy has been incredibly effective in battling HER2 breast cancer, one of the most prevalent tumor types worldwide.
In January, the two companies announced the 18-month overall survival rate during phase 2 testing reached 84%.
And that’s helped boost ZYME’s financial prospects.
 | From our Partners at Banyan Hill Publishing. For 10 years, Ian King has been tracking one of the most devastating actions ever taken against you — and your money.
Here’s what he’s uncovered. |
ZYME Stock: Outstanding Fundamentals With Solid Momentum Zymeworks recently reported a strong close to 2022.
Here are two high points: - Reported total revenue of $412.5 million for the year — that’s a 1,446% jump from its revenue reported in 2021!
- It signed a licensing agreement with Jazz Pharmaceuticals to distribute zanidatamab globally.
That massive increase in revenue shows why ZYME stock scores a 100 on our growth factor of Stock Power Ratings.
ZYME is also a strong value and quality stock — it scores a 95 on our value factor and a 93 on quality.
The average price-to-earnings ratio for the miscellaneous health care industry is 28.7. ZYME trades at a ratio that’s just 15% of that. Remember, lower is better.
Its returns on assets, equity and investments are all positive while its peers average in the red.
Let’s look at ZYME’s momentum — it scores a 92 on that factor:  (Click here to view larger image.) From its September 2022 bottom to now, ZYME stock has climbed 81.3%.
Over the last 12 months, the stock is up 28.3% compared to its peers which have averaged a 21.7% decline.
ZYME stock scores 100 overall on our proprietary Stock Power Ratings system.
That means we’re “Strong Bullish” and expect it to beat the broader market by at least 3X in the next 12 months.
Cancer was the second-leading cause of death in the U.S. in 2021 and the numbers show new cases on the rise.
While it doesn’t command mainstream news coverage, companies continue to race for a cure.
With strong initial clinical studies for its breast cancer treatment, ZYME is a smart addition to your portfolio. Stay Tuned: Is Buy Now, Pay Later the Next Mega Trend? Apple is throwing its weight into the buy now, pay later game. But does that mean this is a market segment worth investing in amid growing strain in the financial system?
I’ll dig into the story a bit more in Monday’s Stock Power Daily, and show you how some of the biggest names in the industry stack up within our proprietary system.
Stay tuned.
Safe trading,
Matt Clark, CMSA®
Chief Research Analyst, Money & Markets
Check Out the Latest From Stock Power Daily: |
Privacy Policy
The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482.
To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/
Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication.
(c) 2023 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471)
Remove your email from this list: Click here to Unsubscribe | | | 
No comments:
Post a Comment